Details for Patent: 7,335,684
✉ Email this page to a colleague
Title: | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Abstract: | The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N--CH2COCH2-CH2CO--OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R2 represents a hydrogen atom or a group R1, and both R2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention. |
Inventor(s): | Gierskcky; Karl E. (Oslo, NO), Moan; Johan (Oslo, NO), Peng; Qian (Oslo, NO), Steen; Harald (Oslo, NO), Warloe; Trond (Oslo, NO), Bjorseth; Alf (Oslo, NO) |
Assignee: | PhotoCure ASA (Oslo, NO) |
Filing Date: | Nov 29, 2005 |
Application Number: | 11/290,275 |
Claims: | 1. A method for the treatment of urinary bladder abnormalities responsive to photochemotherapy in a patient in need thereof, comprising: i) administering to a urinary bladder a composition comprising hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) exposing said lining of the urinary bladder to photoactivating light in the spectrum 300-800 nm.; iii) ascertaining the level of fluorescence; iv) comparing the level of fluorescence to control levels to locate abnormalities in the bladder; and v) treating the abnormalities by (a) continued build up of fluorescence or (b) through further application of the composition at the located site of the abnormalities. 2. The method of claim 1 wherein the abnormality is bladder cancer. 3. The method of claim 2 wherein the photoactivating light is in the spectrum 350-640 nm. 4. The method of claim 3 wherein the ratio of the level of fluorescence of the abnormality to control levels of fluorescence is greater than 8. 5. The method of claim 4 wherein the photoactivating light is applied via an optical fiber inserted through a needle. 6. The method of claim 5 wherein the photoactivating light is applied after surgically accessing the urinary bladder. 7. A method of using hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for the treatment of abnormalities of a urinary bladder in a patient in need thereof, comprising: i) putting in a first container hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) putting in a second container a physiologically acceptable carrier; and iii) putting said first container and said second container in a third container. 8. The method of claim 7 wherein the abnormality is bladder cancer. 9. A method for the treatment of urinary bladder abnormalities responsive to photochemotherapy in a patient in need thereof, comprising: i) administering to a urinary bladder a composition comprising hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) exposing said lining of the urinary bladder to photoactivating light in the spectrum 300-800 nm. and iii) treating the abnormalities by (a) continued build up of fluorescence or (b) through further application of the composition at the located site of the abnormalities. |